Search results
Results from the WOW.Com Content Network
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease. Treatment with donanemab reduced amyloid plaque on average by 84% at 18 months, Lilly found.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. [10] It was developed by Biogen and Eisai. [11] Aducanumab is given via intravenous infusion. [5] Aducanumab was ...
The drug donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks. ... The approval is significant because it adds another treatment ...
In Lilly's large clinical trial, donanemab, given by infusion once a month, slowed progression of memory and thinking problems by 29% overall, roughly comparable to the 27% slowing seen with Leqembi.
The study, published in the Journal of the American Medical Association, concluded that after 76 weeks of treatment, Donanemab was able to slow clinical decline by 35.1% in people with early ...
Interestingly, donanemab treatment resulted in a smaller reduction in the volume of the hippocampus, a brain region that plays a critical role in learning and memory.
Donanemab is not a cure, but clinical trials showed that it slowed the progression of Alzheimer’s, allowing people to live independent lives for longer and safely participate in everyday activities.